LivaNova Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay, we are ready to get started with our next session here this morning at the Jefferies London Healthcare Conference. I am Matt Taylor, the U.S. Medical Supplies and Devices Analyst here at Jefferies, and pleased to welcome the management team from LivaNova. We will have about 25 minutes for a spirited Q&A. We have Alex Shvartsburg, who is the CFO, and Ahmet Tezel, the Chief Innovation Officer. I would like to start, guys, just by giving a little bit of a high-level overview of the LivaNova portfolio, maybe talk about your competitive positioning in both cardiopulmonary and epilepsy, and just talk about how the core business has been performing in those markets.
Yeah. For those who are newer to our story, we are a global med tech company with nearly 50 years of experience in two very strong and very well-performing businesses. We call it our core in cardiopulmonary and epilepsy. Both market-leading positions in both segments. Cardiopulmonary has been a strong growth driver over the last three years, delivering double-digit growth, really driven by several elements. One is we launched a new product in 2023, which is our Essenz capital equipment heart-lung machine. The conversion cycle has been going really well, and we continue to see that as a growth driver going into next year and beyond. We have a market-leading position in capital equipment, about a 70% market share in the overall heart-lung machine installed base. We are about 20% of the way through in upgrading that installed base. So it is going to be a multi-year conversion cycle.
This year, we are going to exit with Essenz representing about 80% of total placements. Next year, going to 100%. Every machine next year will be our Essenz platform. The next growth driver in CP is really our consumables business, and specifically the oxygenator business, which has We have grown our market share from about 30% to about 40% over the last several years. The segment has actually, from a procedure volume standpoint, continues to perform very well. We see that segment growing at about a mid-single-digit level. Historically, it has been flattish to about low single-digit growth in the developed markets. That has actually accelerated over the last few years. Part of it is just pure demographics.
The other part is, I think a lot of patients who historically have received a TAVR procedure are now coming back, are not necessarily good candidates for a replacement TAVR, so they come into a surgical heart valve procedure. So sort of a revision that has accelerated the growth in the developed markets. In the developing markets, basically access to healthcare continues to improve, so that has enabled faster growth. We continue to perform extremely well across both the capital equipment as well as the consumables segment. So that is the CP business. In epilepsy, we have a market-leading position in our neuromodulation technology. We have been in this space for about 30 years, and continue to drive penetration into what is an under-penetrated market segment today. In the U.S., there is approximately 1 million patients diagnosed with DRE. About 10% of those patients are treated with interventional therapies like VNS.
Every year, there is about 900,000 patients diagnosed with DRE across the world, and we have barely scratched the surface of driving penetration in that space. The growth in epilepsy has really accelerated over the course of the last two years. This year specifically driven by improvements in reimbursement in the U.S., where CMS has lifted the reimbursement rates for both new patients and replacement segments by nearly 50%. That has driven growth where hospitals historically who have been sort of challenged by the economics of VNS Therapy, that has improved, and that has helped the growth. Our CORE-VNS clinical data, which has recently been published, has actually gained traction and has really accelerated the volume and really driven the penetration of VNS Therapy. We are pleased with our performance to date.
We see our business as having really strong durable growth over the next several years, which we described at our investor day. We are heading in the right direction.
It has been producing really exciting growth, kind of low double digit, including you recently upgrading your guidance to 9%-10% for this year. Maybe you could talk a little bit more about the sustainability of that growth as we move into 2027, and what are some of the key puts and takes that people should think about?
Same growth drivers will stay intact over the next several years. We also have some innovation that is coming down the pike. Maybe turn it over to Ahmet a little bit to talk about some of what is coming.
Sure. I mean, in each of our business units, we have significant innovation coming. I will start with epilepsy. Next year, we are launching our next-generation implant. It solves the fundamental workflow challenge of today's technology, so it is a significant upgrade. It is not just an iterative upgrade. We have our sleep apnea launch next year as well. We believe the clinical differentiation is extremely strong. The clinical trial had the highest responder rate with the most severe patients enrolled with no exclusions amongst the other available technologies. On the CP side, we have two auxiliary equipment launches. When you do heart-lung machine, there is a third device that does the management of the temperature of the blood, which is called a heater-cooler, and another device does the management of the gases, oxygen and carbon dioxide, which is called the Air Manager.
Today, when you buy a heart-lung machine from LivaNova, you buy Essenz, the actual device, but it comes with the previous generation heater-cooler and Air Manager, so we will upgrade those next year. They will come with a price premium as well. In 2028, we are launching our next-generation oxygenator, which we are very excited about because it is clinically differentiated, and obviously, that will also come with a price premium.
Very good. Let us talk a little bit about how this plays into your margin goals. You talked about the LRP kind of in phases with an expectation to keep operating margins kind of in the low 20s as we move into 2027, but then seeing some inflection really from the sleep launch as we move towards the end of the decade. How should we think about the phasing of the margins as you move through investment period to ramp period, and what could the cadence be like over the next couple years?
Yeah, so during our investor day, we kind of outlined these two phases of our financial framework. The first phase is really about driving top-line growth in mid to high single digits and really growing EPS in line with our top-line growth. So, we drew the line at 20% margin, and basically, any margin expansion that we get from CP or epilepsy, we expect about 300 basis points of margin expansion in CP over the next several years, and about 200 basis points coming from epilepsy. That margin growth will be reinvested in standing up the OSA commercial channels. These are components of our business that we do not have today, so all that excess margin will be reinvested in sleep apnea. Then as sleep apnea scales, so 2028 through 2030, we will expect to generate a fair amount of P&L leverage from that.
We guided sleep apnea to $200 million-$400 million in revenue by 2030. Obviously, the gross margins in Neuromod are very attractive, and so that will drive significant P&L leverage and get us to an operating margin profile in the mid-20s and beyond. So, gives us an opportunity to really leverage our infrastructure that we have built for both epilepsy and CP businesses. You think about a Neuromod platform, that is why I kind of love the platform technology. We are able to leverage our capabilities in R&D, in our supply chain, commercial operations, as well as back office. All of that fixed infrastructure is there to take advantage in driving growth for OSA and hopefully DTD someday.
Ahmet, maybe we could talk a little bit more about the clinical differentiation in sleep. You referenced the high responder rates, and also made some upgrades to the form factor as you go to market, improving the recharge burden and the MRI safety. I think one of the really interesting angles is the PolySync algorithm that you have. Maybe you could expound on that and some of the results you are seeing there, and how you hope that might differentiate you further in the market.
Yeah, sure. One of the main differences of our technology is that we put the electrodes to the proximal end of the nerve, which means we control broader muscle groups compared to other technologies that control the airway. We do not just protrude the tongue, we also strengthen the airway. The way we do that is that we have actually six electrodes, and you can tune the electrodes to adjust different muscles through the hypoglossal nerve. In the original trial, we did not have the algorithms to optimize how you utilize these electrodes. They were utilized, not all six of them, and they were utilized sequentially. Electrode one will turn on, and then electrode four will turn on, for example. Once we had the original data, with that, we achieved 65% responder rate, which is comparable to the market leader today.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
